An Observational Study to Validate the Cumulative Life Course Impairment (CLCI) Instrument (DermCLCI-p) in Adult Participants With Moderate to Severe Chronic Plaque Psoriasis (PsO)
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
154actual
Sites
16
Countries
Belgium, Canada, Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-09 | actual | When the study began enrolling |
| Primary completion | 2025-03-21 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-03-21 | actual | The whole study's end, after follow-up |
| First posted | 2023-07-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Psoriasis
Primary outcomes
what the primary-completion date above is the date OFValidity of the Cumulative Life Course Impairment Instrument (DermCLCI-p)
measured Baseline through Week 28
Reliability of the Cumulative Life Course Impairment Instrument (DermCLCI-p)
measured Baseline through Week 28
Responsiveness of the Cumulative Life Course Impairment Instrument (DermCLCI-p)
measured Baseline through Week 28
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed